Division of Cardiology, Department of Internal Medicine, Tufts Medical Center, Boston, MA, USA.
Department of Medicine/Division of Cardiology, The Cardiovascular Center for Research and Innovation (CVCRI), Acute Circulatory Support Program, Interventional Research Laboratories, Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA, USA.
J Cardiovasc Transl Res. 2021 Jun;14(3):476-483. doi: 10.1007/s12265-020-10078-5. Epub 2020 Oct 19.
In-hospital mortality associated with cardiogenic shock (CS) remains high despite introduction of mechanical circulatory support. In this study, we aimed to investigate whether systemic inflammation is associated with clinical outcomes in CS. We retrospectively analyzed systemic cytokine levels and the neutrophil-to-lymphocyte ratio (NLR), a marker of low-grade inflammation, among 134 patients with CS supported by VA-ECMO or Impella. Sixty-one percent of patients survived CS and either underwent device explantation or were bridged to LVAD or cardiac transplant. IL6 was the predominant circulating cytokine. IL6 levels were reduced after circulatory support in survivors. NLR pre-device implantation was significantly lower in patients with earlier stages of cardiogenic shock. Compared with non-survivors, survivors had a lower pre-device NLR and NLR was independently predictive of survival after adjusting for other covariates. In summary, NLR is a widely available marker of inflammation and correlates with in-hospital mortality among patients with cardiogenic shock requiring percutaneous mechanical circulatory support. Graphical Abstract Survivors present with lower NLR levels prior to percutaneous device implantation. Both survivors and non survivors present with elevated IL6 levels. IL6 levels decrease after percutaneous support (ECMO or Impella) only in survivors and continue to rise in non-survivors.
尽管已经引入了机械循环支持,但与心源性休克(CS)相关的院内死亡率仍然很高。在这项研究中,我们旨在研究全身炎症是否与 CS 的临床结果相关。我们回顾性分析了 134 例接受 VA-ECMO 或 Impella 支持的 CS 患者的全身细胞因子水平和中性粒细胞与淋巴细胞比值(NLR),这是一种低度炎症的标志物。61%的患者存活 CS 并接受了设备去除或桥接到 LVAD 或心脏移植。IL6 是主要的循环细胞因子。在幸存者中,循环支持后 IL6 水平降低。在设备植入前,心源性休克早期阶段患者的 NLR 明显较低。与非幸存者相比,幸存者的 NLR 较低,并且在调整其他协变量后 NLR 是存活的独立预测因素。总之,NLR 是一种广泛可用的炎症标志物,与需要经皮机械循环支持的 CS 患者的院内死亡率相关。
在接受经皮设备植入前,幸存者的 NLR 水平较低。幸存者和非幸存者的 IL6 水平均升高。仅在幸存者中,经皮支持(ECMO 或 Impella)后 IL6 水平下降,而非幸存者中继续升高。